데이터를 보충하는 중입니다. 잠시 후 페이지를 새로 고치면 최신 내용을 볼 수 있습니다
기본 정보
- CAS
214766-78-6- 표준 SMILES
CC(=O)N[C@H](Cc1ccc2ccccc2c1)C(=O)N[C@H](Cc1ccc(Cl)cc1)C(=O)N[C@H](Cc1cccnc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(NC(=O)[C@@H]2CC(=O)NC(=O)N2)cc1)C(=O)N[C@H](Cc1ccc(NC(N)=O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O- InChIKey
MEUCPCLKGZSHTA-XYAYPHGZSA-N- 분자식
- C82H103ClN18O16
- 평균 분자량
- 1,632.289 g/mol
- 단동위원소 질량
- 1,630.7487969
이름 및 식별자
- 우선 이름
- Degarelix
- 영어명
- Degarelix
- 분자식
- C82H103ClN18O16
- 분자량
- 1632.26
이름 및 동의어
Degarelix acetateFirMagonDikarekDEGARELIXDegarelix-d7Peptides AcetateDegarelix impurityDEGARELIX USP/EP/BPDegarelix acetate saltDegarelix, Degarelix acetate
데이터베이스 식별자
- CAS
214766-78-6- PubChem CID
- 16136245
- DTXSID
DTXSID801026401- ChEMBL
CHEMBL415606- ChEBI
CHEBI:135961- UNII
- SX0XJI3A11
- EC Number
- 807-277-4
- Nikkaji
- J1.951.873F
물성
물리화학적 성질
- 밀도
- 1.325 · 1.325±0.06 g/cm3(Predicted)
- 저장 조건
- -20 °C · Keep in dark place,Inert atmosphere,Store in freezer, under -20°C
- 용해도
- 10 · DMSO:10.0(Max Conc. mg/mL);6.13(Max Conc. mM)H2O:25.0(Max Conc. mg/mL);15.32(Max Conc. mM)
- 산도 계수 (pKa)
- 10.38 · 10.38±0.40(Predicted)
- 물리적 상태
- Solid
- 색상
- White to off-white
- InChIKey
- MEUCPCLKGZSHTA-XYAYPHGZSA-N
안전 및 규제
안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.
안전 데이터
- 유해 물질 데이터
- 214766-78-6(Hazardous Substances Data)
화학 및 산업
응용 분야
개요Antagonists of GnRH have proven to be an effective therapy for hormonally regulated cancers, such as prostate and some types of breast. As analogs of GnRH, they bind competitively and reversibly to GnRH receptors in the pituitary gland, thereby blocking the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). In men, the reduction of LH triggers the ablation of testosterone secretion from the testes, and these castration-like levels have been essential in the effective management of advanced prostate cancer. In comparison to GnRH agonists, antagonists do not suffer from a potential flare of the disease as a result of an initial stimulation of the hypothalamic-pituitary-gonadal axis prior to down-regulation of the GnRH receptor. Moreover, GnRH antagonists provide beneficial effects more rapidly postdosing and result in a more efficient suppression of gonadotropin levels. With this in mind, degarelix acetate has been launched as a third-generation GnRH antagonist for the treatment of prostate cancer, and it joins other third-generation agents, ganirelix and cetronelix, on the market.
용도Degarelix, is a competitive and reversible gonadotropin-releasing hormone receptor (GnRHR) antagonist.
공급사100 곳
湖北永阔科技有限公司027-59223108 15972152991 · [email protected]
合肥翰刚医药科技有限公司+8618062405514 · [email protected]
Hangzhou Go Top Peptide Biotech0571-88211921 · [email protected]
上海遐瑞医药科技有限公司+86-021-61551413 · [email protected]
Baoji Guokang Healthchem co.,ltd+8615604608665 15604608665 · [email protected]
Hebei Yanxi Chemical Co., Ltd.+86-17531190177 · [email protected]
관련 반응
0건
현재 필터 조건에 해당하는 반응 기록이 없습니다.
화합물 노트
불러오는 중…